Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
公司代碼INDV
公司名稱Indivior PLC
上市日期Dec 24, 2014
CEOCiaffoni (Joseph J)
員工數量1030
證券類型Ordinary Share
年結日Dec 24
公司地址234 Bath Road
城市SLOUGH
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United Kingdom
郵編SL1 4EE
電話448043791090
網址https://www.indivior.com/en
公司代碼INDV
上市日期Dec 24, 2014
CEOCiaffoni (Joseph J)